Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis

Jingyi Jia; Yue Zeng; Yongling Ji; Hui Zhu; Rui Meng; Bing Xia; Yunfeng Wang; Tianle Shen; X. Su; Tongfang Zhou; Y. Lu; Lei Zhao; Zhangru Yang; X. Fu; Xuwei Cai

doi:10.3389/fimmu.2026.1818306

March 10, 2026SHILAP Revista de lepidopterologíaOpen Access

Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer.
Conducted a multi-center analysis
Compared outcomes between radiotherapy (RT) group and non-radiotherapy (Non-RT) group
Analyzed overall survival (OS) and progression-free survival (PFS) rates after propensity score matching (PSM)
One-year OS rates were 80.4% in the RT group compared to 62.2% in the Non-RT group
Two-year OS rates were 50.9% in the RT group compared to 34.1% in the Non-RT group
PFS was significantly longer after PSM in the RT group (12.7 months) compared to the Non-RT group (6.5 months), with HR=0.47 and p<0.001

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Multi-center analysis shows improved progression-free survival in extensive-stage small-cell lung cancer, suggesting combined treatment is beneficial.

Abstract

"[The one-year and two-year OS rates were 80.4% and 50.9%, respectively, in RT group, compared to 62.2% and 34.1%, respectively, in Non-RT group.]" [The PFS data after PSM was incorrectly copied as OS data]. A correction has been made to the section [Results, Survival outcomes, Paragraph 3]: "[After PSM, significant improvements in PFS(Figure3C,12.7months vs 6.5months, HR= 0.47, 95%CI:0.39-0.56, p<0.001)]" The original version of this article has been updated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jia et al. (2026) studied this question.

synapsesocial.com/papers/69b3ab6e02a1e69014ccc475 https://doi.org/10.3389/fimmu.2026.1818306

View Full Paper

Ask AI

Bookmark

Share

Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading